215 related articles for article (PubMed ID: 29716829)
21. Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy.
IJsselsteijn ME; Sanz-Pamplona R; Hermitte F; de Miranda NFCC
Mol Aspects Med; 2019 Oct; 69():123-129. PubMed ID: 31136750
[TBL] [Abstract][Full Text] [Related]
22. Combating colorectal cancer with immunotherapy: Where are we?
Gupta R; Bhatt LK; Prabhavalkar KS
Drugs Today (Barc); 2019 Aug; 55(8):513-528. PubMed ID: 31461088
[TBL] [Abstract][Full Text] [Related]
23. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
[TBL] [Abstract][Full Text] [Related]
24. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
Atreya I; Neurath MF
Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
[TBL] [Abstract][Full Text] [Related]
25. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
26. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
27. Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Bauer C; Kühnemuth B; Duewell P; Ormanns S; Gress T; Schnurr M
Cancer Lett; 2016 Oct; 381(1):259-68. PubMed ID: 26968250
[TBL] [Abstract][Full Text] [Related]
28. [Development of immune checkpoint inhibitor in colorectal cancer].
Kitano S
Nihon Rinsho; 2016 Nov; 74(11):1818-1820. PubMed ID: 30550688
[TBL] [Abstract][Full Text] [Related]
29. Cellular immunotherapy of cancer: an overview and future directions.
Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
[TBL] [Abstract][Full Text] [Related]
30. Tumor Microenvironment Remodeling by 4-Methylumbelliferone Boosts the Antitumor Effect of Combined Immunotherapy in Murine Colorectal Carcinoma.
Malvicini M; Fiore E; Ghiaccio V; Piccioni F; Rizzo M; Olmedo Bonadeo L; García M; Rodríguez M; Bayo J; Peixoto E; Atorrasagasti C; Alaniz L; Aquino J; Matar P; Mazzolini G
Mol Ther; 2015 Sep; 23(9):1444-55. PubMed ID: 26105158
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in ovarian cancer.
Krishnan V; Berek JS; Dorigo O
Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
[TBL] [Abstract][Full Text] [Related]
32. Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.
Roelands J; Kuppen PJK; Vermeulen L; Maccalli C; Decock J; Wang E; Marincola FM; Bedognetti D; Hendrickx W
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29064420
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy in colorectal cancer: What have we learned so far?
Sanchez-Castañón M; Er TK; Bujanda L; Herreros-Villanueva M
Clin Chim Acta; 2016 Sep; 460():78-87. PubMed ID: 27350293
[TBL] [Abstract][Full Text] [Related]
34. Review on the immunotherapy strategies against metastatic colorectal carcinoma.
Signorini L; Delbue S; Ferrante P; Bregni M
Immunotherapy; 2016 Oct; 8(10):1245-61. PubMed ID: 27605072
[TBL] [Abstract][Full Text] [Related]
35. High-resolution genomic analysis: the tumor-immune interface comes into focus.
Havel JJ; Chan TA
Genome Biol; 2015 Mar; 16(1):65. PubMed ID: 25853850
[TBL] [Abstract][Full Text] [Related]
36. Single-cell immune profiling reveals new insights into colorectal cancer.
Lönnberg T; Stubbington MJ
Immunol Cell Biol; 2019 Mar; 97(3):241-243. PubMed ID: 30791147
[No Abstract] [Full Text] [Related]
37. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
Blair AB; Murphy A
Curr Probl Cancer; 2018; 42(1):49-58. PubMed ID: 29501212
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in human colorectal cancer: Challenges and prospective.
Sun X; Suo J; Yan J
World J Gastroenterol; 2016 Jul; 22(28):6362-72. PubMed ID: 27605872
[TBL] [Abstract][Full Text] [Related]
40. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
